Furthermore, we divided all high-risk AML patients into two groups according to the miR-182 expression level and observed a significant inverse correlation to CEBPA expression (Fig. 3e), the percentage of bone marrow (BM) blasts (Fig. 3g) and peripheral blood (PB) blasts (Fig. 3h). This evidence concerns the gene CEBPA and acute myeloid leukemia.